Axsome Therapeutics, Inc. (Nasdaq: AXSM) is a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system, or CNS, disorders. By focusing on this therapeutic area, the company is addressing significant and growing markets where current treatment options are limited or inadequate. The company’s product candidate portfolio includes two late-stage candidates, AXS-02 and AXS-05, which will have multiple indications. The company aims to become a fully integrated biopharmaceutical company that develops and commercializes differentiated therapies that expand the treatment options available to caregivers and improve the lives of patients living with pain and other CNS disorders. For more information, visit the company’s website at www.axsome.com